MedWatch, an industry leader for white-glove concierge member advocacy and support services, was recently selected to support a next-generation negotiated rate calculation and pricing solution, providing healthcare stakeholders evidence-based, commercially valid, equitable market rates to providers and patients. MedWatch is supporting TALON, a pioneer in ethical healthcare price transparency, to empower the healthcare market with a fair, transparent price, for the first self-funded employer group deployment.
Developed internally at TALON, the Universally Acceptable Payment Amount™, or UAPA™, leverages advanced machine learning to ingest and transform massive amounts of healthcare pricing data, curating a single, evidence-based rate that patients and providers can trust. Unlike other contracted rates within healthcare, UAPA eliminates the “network discount” concept, and instead reflects actual commercial acceptance.
Health Technology Insights: Vit-Best Nutrition Appoints New President
Derived from real, commercial prices spanning over 400+ payers, UAPA lands at an equitable midpoint—not artificially low or high. Providers see a realistic rate they already accept, employers achieve predictable spend, and patients receive fair, ethical, transparent pricing.
“I’m very excited for the future of the healthcare industry as a result of our development and first deployment of UAPA” commented Mark Galvin, CEO of TALON, “UAPA will spark a massive transition in the healthcare industry, fostering a more efficient, free market driven financial environment for healthcare patients and providers. Selecting MedWatch to support the first real-world deployment was an easy decision, given their reputation in the industry and their gold standard support and advocacy on behalf of healthcare consumers.”
Health Technology Insights: Lion TCR’s Liocyx-M004 Approved for Global Phase 2 HBV Liver Cancer Trial
“MedWatch delivers lasting value built on compassion, transparency, and a deep understanding of what it truly means to care. TALON’s UAPA is perfectly aligned with our organizational values and commitment to patients” said Sally-Ann Polson, President and CEO at MedWatch. “When paired with our Pathways Concierge solution, patients leveraging UAPA will benefit from outstanding clinical outcomes, increased trust and loyalty between patient and provider, and meaningful reduction in healthcare spend.”
Health Technology Insights: QuantalX Neuroscience Secures CE MDR Approval for Brain Health in the EU
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source: PR Newswire
